Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 3Gynecologic 3Head & Neck 2Gastrointestinal 2Breast 2CNS 1

Conditions

Colorectal Neoplasms 315Pancreatic Neoplasms 186Carcinoma, Hepatocellular 116Stomach Neoplasms 110Colonic Neoplasms 84Esophageal Neoplasms 80Carcinoma, Non-Small-Cell Lung 80Breast Neoplasms 78Rectal Neoplasms 75Ovarian Neoplasms 62Neoplasm Metastasis 59Lung Neoplasms 58Neoplasms 54Cholangiocarcinoma 53Melanoma 45Liver Neoplasms 45Gastrointestinal Neoplasms 43Prostatic Neoplasms 42Biliary Tract Neoplasms 37Endometrial Neoplasms 33Squamous Cell Carcinoma of Head and Neck 31Sarcoma 29Carcinoma, Renal Cell 29Esophageal Squamous Cell Carcinoma 27Uterine Cervical Neoplasms 26Adenocarcinoma Of Esophagus 24Head and Neck Neoplasms 23Urinary Bladder Neoplasms 22Small Cell Lung Carcinoma 20Gastrointestinal Stromal Tumors 17

Interventions

tivozanib 1lorlatinib 1encorafenib 1binimetinib 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × Gastrointestinal × 30 days × Clear all
NCT04800822 2026-06-04

PF-07284892 in Participants With Advanced Solid Tumors

Pfizer

Phase 1 Terminated
53 enrolled
CNSGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neurofibromatosis 1, Hereditary Sensory and Autonomic Neuropathies, Colorectal Neoplasms

NCT04645160 2026-06-03

Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
31 enrolled
Gastrointestinal

Bile Duct Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡